ライフサイエンスコーパス: neurocognitive test

1 standardized continuous scores on individual neurocognitive tests.

2 uestionnaire and a battery of 6 standardized neurocognitive tests.

3 h HIV worldwide have poor outcomes on formal neurocognitive tests.

4 affected, and the mice performed normally in neurocognitive tests.

5 on the UPSA, the ADCS-ADL, and a battery of neurocognitive tests.

6 s would be associated with deficits found by neurocognitive tests.

7 DTI on a 3.0 Tesla scanner and a battery of neurocognitive tests.

8 aluated by MRI, neurologic examinations, and neurocognitive tests.

9 and were age >/= 18 years were recruited for neurocognitive testing.

10 tcome was based on clinical observations and neurocognitive testing.

11 is, 18 years [11 to 42 years]) and completed neurocognitive testing.

12 comes (death or severe disability precluding neurocognitive testing: 19% [68/349] vs 18% [63/351] wit

13 ited no sequelae on physical examination and neurocognitive tests a mean of 6.0 years after infection

14 no significant differences in the results of neurocognitive testing among the three treatment groups

15 The authors conducted neurocognitive testing and diffusion tensor imaging in 2

16 luations were conducted with age-appropriate neurocognitive testing and quantitative magnetic resonan

17 d between the two groups and correlated with neurocognitive tests and clinical performance in patient

18 nt repeated structural MRI and comprehensive neurocognitive testing, and they were genotyped for four

19 d state assessment (Profile of Mood States), neurocognitive tests, and serologic examination.

20 s after their diagnosis, survivors completed neurocognitive testing, another brain MRI, and their par

21 Neurocognitive tests are a relatively sensitive measure

22 Neurocognitive tests assessing IQ, EF, and episodic memo

23 The patients were assessed with a battery of neurocognitive tests at baseline and 12 weeks after begi

24 -resolution structural MRI and comprehensive neurocognitive tests at baseline and 18 months and conti

25 90.5% patients had impairment of one or more neurocognitive tests at baseline.

26 Both groups were administered a neurocognitive test battery and a standardized RCC measu

27 A neurocognitive test battery included domain-specific ass

28 d examined through the use of a computerized neurocognitive test battery that provided measures of ac

29 A neurocognitive test battery was used to assess speed of

30 s, compared the findings to performance on a neurocognitive test battery, and found that N-acetylaspa

31 Patients received neurocognitive testing before, 1, and 6 months after car

32 ctural differences have been associated with neurocognitive testing deficiencies.

33 urocognitive performance, measured by direct neurocognitive tests (Delis-Kaplan Executive Function Sy

34 owever, the performance of the two groups on neurocognitive tests did not significantly differ.

35 Neurocognitive tests, driving simulation, and road tests

36 tly associated with worse performance on all neurocognitive tests except that of sustained attention.

37 tly associated with worse performance on all neurocognitive tests except that of verbal memory.

38 confirmed 22q11.2 deletions (N=44) underwent neurocognitive testing following Val(158)Met genotyping

39 Monthly neurocognitive testing for memory, executive function, a

40 A subset of 108 patients had neurocognitive testing for processing speed, memory and

41 Neurocognitive testing, functional magnetic resonance im

42 nts (67%) with available long-term follow-up neurocognitive testing had severe impairment in at least

43 us cutoffs, a combination of scores on the 3 neurocognitive tests identified 16 (20%) of the mothers

44 itative magnetic resonance imaging (MRI) and neurocognitive testing in multiple sclerosis (MS) patien

45 Neurocognitive tests included measures of working memory

46 Neurocognitive tests included the Consortium to Establis

47 146 participants (75 PI-mono) had neurocognitive testing (median time after randomization

48 ribe currently used imaging, functional, and neurocognitive testing modalities and to better understa

49 This knowledge may help guide neurocognitive testing of specific neurological domains

50 tinent users have been found to do poorly on neurocognitive tests of attention and motor skills, both

51 exploratory outcomes included performance on neurocognitive tests of executive function, memory, atte

52 orrelate with poorer performance on selected neurocognitive tests of white matter function.

53 Longitudinal neurocognitive test performance in 4 domains (verbal com

54 Baseline and follow-up neurocognitive test performance was analyzed for all boy

55 Neurocognitive test results were below normal expectatio

56 RT, we examined the association of NAWM with neurocognitive test results.

57 Neurocognitive testing revealed small decrements in some

58 Neurocognitive tests revealed impaired performance acros

59 ld TBI and vestibular symptoms had decreased neurocognitive test scores (P < .05) and FA values in th

60 lar convergence insufficiency had diminished neurocognitive test scores (P < .05) and FA values in th

61 elberger State-Trait Anxiety Inventory); and neurocognitive test scores (Rey Auditory Verbal Learning

62 Neurocognitive test scores of memory, fine motor speed,

63 dings were correlated with symptom severity, neurocognitive test scores, and time to recovery with th

64 ities were correlated with symptom severity, neurocognitive test scores, and time to recovery with th

65 Low performance on neurocognitive tests specific for dorsolateral prefronta

66 pe 1 diabetes is associated with deficits on neurocognitive testing that suggest central white matter

67 d with the CHR phase, measure the ability of neurocognitive tests to predict transition to psychosis,

68 oach highlights the need for development of "neurocognitive" tests to probe the function of component

69 sychological symptom reports, and results of neurocognitive testing using validated instruments were

70 Neurocognitive testing was conducted in 350 pediatric le

71 Inpatient neurocognitive testing was feasible in pediatric MTBI pa

72 Neurocognitive testing was performed at baseline and at

73 In a prospective cohort study, neurocognitive testing was performed in 408 healthy chil

74 FA maps were obtained and neurocognitive testing was performed in 74 patients with

75 ologic progression scoring that incorporated neurocognitive tests was implemented successfully.

76 dized investigator neurologic assessment and neurocognitive testing were evaluated.

77 In 261 patients who underwent CABG, neurocognitive tests were performed preoperatively (at b

78 faction, color vision, sleep parameters, and neurocognitive testing) were assessed at baseline.

79 Patients with mTBI underwent serial neurocognitive testing with Immediate Post-Concussion As

80 Diffusion-tensor imaging and serial neurocognitive testing with the Immediate Post-Concussio